Efficacy of Dexamethasone in Treatment of Meconium Aspiration Syndrome
Objective: To determine efficacy of dexamethasone in treatment of meconium aspiration syndrome.
Study design: Randomized control trial. Place and duration: Services hospital, Neonatal unit, Lahore. During time span of 1st January to 30th June 2021.
Material and methods Total 100 neonates were randomly divided in two groups. Group A (n=50) was treated with dexamethasone (Cases) and Group B (n=50) served as control. Dexamethasone was given in dose of 0.2mg/kg, 12 hourly for 7 days after confirmation of diagnosis. Infants present in clinical trial were evaluated by ventilation duration (invasive and non-invasive), oxygen therapy and hospital stay.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Punjab
-
Lahore, Punjab, Pakistan
- Services Hospital Lahore
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Term and Post-Term babies who met the operational definition of MAS (inborn)
- Presenting within 24 hours of life
Exclusion Criteria:
- Preterm babies or babies with congenital malformations
- Preterm babies or babies with dysmorphism
- Preterm babies or babies with hypoxic-ischemic encephalopathy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group A (Dexamethasone Group),
Group A (Case Group) was given dexamethasone i.e., 0.2 mg per kg per day every 12 hours for 7 days intravenously.
All treatment strategies were same in both groups but steroid was given to group A
|
Randomized clinical trial
Other Names:
|
|
No Intervention: Group B (Control Group)
Group B (Control group), received routine treatment.No dexamethasone
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of days required for ventilation in participants
Time Frame: 7 days
|
The purpose of study was to measure number of days required for ventilation in participants
|
7 days
|
|
The number of days required for oxygen therapy in participants
Time Frame: 7 days
|
The purpose of study was to measure number of days required for oxygen therapy in participants
|
7 days
|
|
The number of days required for hospitalization in participants
Time Frame: 7 days
|
The purpose of study was to measure number of days required for hospitalization in participants
|
7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Uzair Qureshi, FCPS, Services Institute of Medical Sciences, Lahore
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Infant, Newborn, Diseases
- Fetal Diseases
- Pregnancy Complications
- Lung Injury
- Meconium Aspiration Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Dexamethasone
- Dexamethasone acetate
- BB 1101
Other Study ID Numbers
Other Study ID Numbers
- IRB/2021/771/SIMS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.